Denka (4061) · InitiativeRestated
Joint research on an influenza vaccine using next-generation mRNA technology
First written in FY2024. 1 of 2 entries say "Restated". Latest entry: FY2026.
2entries
3years
0from disclosures
How it moved
Same theme, other companies
Joint research with VLP Therapeutics Japan and the Research Foundation for Microbial Diseases, Osaka University, on a next-generation mRNA influenza vaccineA theme 1 companies write about · 0 as a headwind · 1 as a tailwind
No other company in this theme has enough history to compare yet.
Full recordFilings, disclosures and news, newest first
- FY2026RestatedAnnual report
「In addition, we are pursuing research and development of next-generation mRNA influenza vaccines through joint research with external institutions.」
Continuing joint research on influenza vaccines using next-generation mRNA technology. - FY2024First statedAnnual report
「We entered into a joint research agreement with VLP Therapeutics Japan Co., Ltd. and the Research Foundation for Microbial Diseases, Osaka University, concerning the development of influenza vaccines using next-generation mRNA technology.」
Entered into joint research agreements with VLP Therapeutics Japan and the Research Foundation for Microbial Diseases, Osaka University, and began developing influenza vaccines using next-generation mRNA technology.